ライフサイエンスコーパス: end-stage renal failure

1 nts suffering insulin-dependent diabetes and end stage renal failure.

2 standard for some patients with diabetes and end stage renal failure.

3 transplantation is the optimum treatment for end-stage renal failure.

4 a major clinical problem that can result in end-stage renal failure.

5 SRNS regularly progresses to end-stage renal failure.

6 ve treatment, and patients often progress to end-stage renal failure.

7 the best treatment option for patients with end-stage renal failure.

8 g to chronic kidney disease and occasionally end-stage renal failure.

9 tion and is essential for the progression to end-stage renal failure.

10 n patients with type 1 diabetes mellitus and end-stage renal failure.

11 rotic syndrome (SRNS) is a frequent cause of end-stage renal failure.

12 eatment of choice for diabetic patients with end-stage renal failure.

13 ause of acute kidney injury that can lead to end-stage renal failure.

14 ammatory syndromes and frequently results in end-stage renal failure.

15 opment of proteinuria and the progression to end-stage renal failure.

16 ysplasia is the principal cause of childhood end-stage renal failure.

17 , and atherosclerosis, the leading causes of end-stage renal failure.

18 and pharmacodynamics of RTX in patients with end-stage renal failure.

19 f most chronic kidney disease progression to end-stage renal failure.

20 ountered forms of renal disease that lead to end-stage renal failure.

21 lomerulosclerosis, which ultimately leads to end-stage renal failure.

22 ier initiation of dialysis for patients with end-stage renal failure.

23 sion of chronic renal diseases that leads to end-stage renal failure.

24 tely limit the use of peritoneal dialysis in end-stage renal failure.

25 s 1 in 1000 individuals and often results in end-stage renal failure.

26 Diabetic nephropathy is a leading cause of end-stage renal failure.

27 renal replacement therapy for children with end-stage renal failure.

28 rogression to overt nephropathy and eventual end-stage renal failure.

29 e are the optimum form of vascular access in end-stage renal failure.

30 gression of renal failure and the time until end-stage renal failure.

31 isease is the most common cause of childhood end-stage renal failure, a condition that is lethal with

32 fficiency in affected patients progresses to end-stage renal failure, a highly morbid state requiring

33 ischemic kidney damage, acute kidney injury, end-stage renal failure, acute renal transplant rejectio

34 KTx should be offered for end-stage renal failure after LTx, even in the presence

35 End-stage renal failure after successful liver transplan

36 ohort study of outcomes in 221 patients with end-stage renal failure aged 70 years or over recruited

37 dly affects glomeruli and progresses towards end stage renal failure and multiple organ dysfunction.

38 man EPO (rHuEPO) for anaemia associated with end-stage renal failure and cancer chemotherapy, also ha

39 lthy individuals and patients with diabetes, end-stage renal failure and familial hypercholesterolaem

40 ciated with apoAI Gly26Arg, which had led to end-stage renal failure and progressive liver dysfunctio

41 consecutive AAGN patients who had developed end-stage renal failure and received a kidney allograft

42 tubulointerstitial nephritis culminating in end-stage renal failure and urothelial malignancy.

43 ssive kidney fibrosis contributes greatly to end-stage renal failure, and no specific treatment is av

44 ns unanswered whether diabetic patients with end-stage renal failure are better served by LRD or SPK.

45 The leading causes of albuminuria and end-stage renal failure are secondary to abnormalities i

46 n 66 patients with abnormal bladders who had end-stage renal failure as a consequence of urologic abn

47 velopment of both chronic kidney disease and end-stage renal failure, but the molecular details under

48 se mice developed proteinuria at 3 weeks and end stage renal failure by 5 weeks after birth.

49 End stage renal failure can be seen very rare.

50 The rate of progression to end-stage renal failure can be delayed, but progression

51 By 3 weeks of age the mice develop severe end stage renal failure characterized by both tubulointe

52 e of soluble CR1 in a pediatric patient with end stage renal failure demonstrated its safety and abil

53 Clinical practice guidelines (CPGs) for end-stage renal failure (ESRD) were recently published,

54 Eleven patients (24%) had end-stage renal failure (ESRF) at presentation; of these

55 ber of patients with hypertension-associated end-stage renal failure (ESRF) continues to increase des

56 reditary glomerulonephritis which results in end-stage renal failure (ESRF) in most cases.

57 cause renal dysfunction that may progress to end-stage renal failure (ESRF).

58 ) disease are at risk for the development of end-stage renal failure from the treatment of localized

59 For those patients with end-stage renal failure, GCV concentrations fell during

60 The growth in the prevalence of end-stage renal failure has been accompanied with a rise

61 patients could be decreased before and after end-stage renal failure has occurred.

62 nical renal involvement rarely progresses to end-stage renal failure; however, recent studies suggest

63 r common finding in kidneys that progress to end-stage renal failure; however, the effect of HGF on i

64 k factors of upper limb ischemia - diabetes, end-stage renal failure, hyperparathyroidism, or even sy

65 R) and urinary tract infection can result in end-stage renal failure, hypertension, or both.

66 shed reports of transplantation secondary to end-stage renal failure in adult patients with systemic

67 e urinary tract are the most common cause of end-stage renal failure in children and account for a si

68 reflux nephropathy (RN) causes up to 15% of end-stage renal failure in children and adults.

69 dder outflow obstruction is a major cause of end-stage renal failure in children and is associated wi

70 nstitute the most frequent genetic cause for end-stage renal failure in children and young adults.

71 n terms of pediatric health care costs, with end-stage renal failure in children estimated to cost >$

72 sease, is the most frequent genetic cause of end-stage renal failure in children.

73 sease, is the most frequent genetic cause of end-stage renal failure in the first three decades of li

74 recessive cystic renal disease that leads to end-stage renal failure in the first two decades of life

75 nephropathy (DN) became the leading cause of end-stage renal failure in the Western world.

76 targeted treatments are lacking, progress to end stage renal failure is a common final outcome.

77 The rate of end-stage renal failure is disproportionately high in th

78 he prevalence of atrial fibrillation (AF) in end-stage renal failure is high, with an increased risk

79 l function in most patients, and the risk of end-stage renal failure is low.

80 e and progression of cyclosporine-associated end-stage renal failure necessitating chronic hemodialys

81 chronic kidney disease (CKD) and consequent end-stage renal failure necessitating renal replacement

82 End stage renal failure occurred in 23 children, 6 of wh

83 veloped nephrotic syndrome and progressed to end-stage renal failure over 1.5 years.

84 tanes were found to be 8.3-fold higher in an end-stage renal failure patient on hemodialysis and urin

85 OxPL in human peritoneal dialysis fluid from end-stage renal failure patients inhibited phagocytosis

86 Of these, 19 (6.5%) developed end-stage renal failure requiring chronic hemodialysis.

87 ths after transplantation and progression to end-stage renal failure, requiring hemodialysis in 6.5%

88 Three patients developed end-stage renal failure secondary to calcineurin nephrot

89 In end-stage renal failure, the net clinical benefit of VKA

90 ugh Col4a3;Tsp1 DKO mice did progress toward end-stage renal failure, their kidneys exhibited distinc

91 idney donors must be paramount in addressing end-stage renal failure through living kidney donation.

92 It has enabled patients with end-stage renal failure to survive for years, in many ca

93 Twenty-two patients with T1D and end-stage renal failure undergoing islet transplantation

94 The median age at end stage renal failure was 22.5 years (range, 10-38 yea

95 atients with combined MCP mutation developed end stage renal failure within 3 years from onset compar

96 deterioration of kidney function, leading to end-stage renal failure within 3 years.

97 s nephronophthisis, typically progressing to end-stage renal failure within the first two decades of